New paradigm – a first in class multi-target approach
Yiviva is a clinical-stage biotech, co-founded by Yale University, developing first-in-class therapeutics using a multi-targeted approach to treat complex diseases.
There is a need for new approaches to treat unmet medical needs, and there is an opportunity for innovation because:
- Our bodies are inter-connected systems.
- Aging-associated diseases are complex and can have heterogeneous causes.
- Conventional reductionist approaches often oversimplify the treatment of complex diseases, which can have many causes. Conventional Western medicine using a single chemical entity to target a single target are often insufficient – with limited efficacy and serious side effects for patients.
- Traditional Medicine approaches which treat a body holistically may lack scientific evidence to validate efficacy. And botanical medicines, which may be comprised of many components, often are prepared without sufficient and consistent quality control.
Modern Science + Ancient Wisdom = Future Medicines
Patient focused approach
We believe in treating the patient, not just the disease, to improve health and quality of life.
Evidence-based polychemical medicines to treat multiple causes synergistically
Validated through rigorous preclinical and clinical studies using the latest advances in genomic, metabolomic, and systems biology approaches.
High-Quality Botanical Drugs
Manufactured to meet US FDA and CFDA regulatory standards.
Innovation through Collaboration
Teaming with world-class scientists, doctors, and institutions.